Literature DB >> 12506296

Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk.

Mohamed A Daw1, Mohamed A Elkaber, Aisha M Drah, Mansour M Werfalli, Abdulgadir A Mihat, Ismail M Siala.   

Abstract

OBJECTIVES: To determine the prevalence of hepatitis C virus (HCV) antibodies among 5 different population groups including; healthy individuals, blood donors, hospital health care workers, renal dialysis patients and multiple blood transfusion group. To compare the ratios, relative and attributable risk among these groups. To outline a specific policy to reduce the potential risk of HCV among the different groups studied.
METHODS: A prospective study was carried out in the Department of Microbiology, Faculty of Medicine, Tripoli, Libya, over a 2 year period for 1999 to 2001, to determine the prevalence of HCV-antibodies in sera collected from 5 distinct groups using enzyme-linked immunosorbent assay test. The groups included 800 healthy adults, 1200 individuals of blood donors, 459 hospital health care workers, 200 patients on renal dialysis and multiple blood transfusion group which included 250 patients. The prevalence of HCV was correlated with relative and attributable risk that contributed to the infectivity of HCV.
RESULTS: A total of 2909 individuals participated in this study with 1.6:1 male to female ratio. The prevalence of HCV varied from one group to another. It was found to be 1.6% among the general population, 1.2% among blood donors, 2% among hospital health care workers, 20.5% among renal dialysis patients and 10.8% in the multiple blood transfusion group. The relative risk and attributable risk among these groups varies from 1.25 to 12.8 and from 0.4-18.9.
CONCLUSIONS: This study underlines the prevalence of HCV among different groups. The prevalence varies from one group to another, being the lowest among the blood donors and general population and the highest among the higher risk group in particular the renal dialysis patients. Specific measures should be implemented to reduce such risks. These may include specific programs for medical education, a meticulous infection control system in the hospitals, a registry program and clinical follow-up for patients positive for HCV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12506296

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  20 in total

1.  Modelling the prevalence of hepatitis C virus amongst blood donors in Libya: An investigation of providing a preventive strategy.

Authors:  Mohamed A Daw; Amira Shabash; Abdallah El-Bouzedi; Aghnya A Dau; Moktar Habas
Journal:  World J Virol       Date:  2016-02-12

Review 2.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 3.  Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population.

Authors:  S Ramia; N M Melhem; K Kreidieh
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

4.  Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients.

Authors:  Hana A Elasifer; Yossif M Agnnyia; Basher A Al-Alagi; Mohamed A Daw
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

5.  A shield against a monster: Hepatitis C in hemodialysis patients.

Authors:  Seyed-Moayed Alavian
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

Review 6.  Management of hepatitis C virus infection in hemodialysis patients.

Authors:  Yue-Cheng Yu; Yue Wang; Chang-Lun He; Mao-Rong Wang; Yu-Ming Wang
Journal:  World J Hepatol       Date:  2014-06-27

7.  Hemodialysis patients: a high risk group for hepatitis C.

Authors:  Ah Omar; K Ashawesh
Journal:  Libyan J Med       Date:  2008-12-01       Impact factor: 1.657

8.  Viral hepatitis a to e in South mediterranean countries.

Authors:  Sanaa M Kamal; Sara Mahmoud; Tamer Hafez; Runia El-Fouly
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-02-10       Impact factor: 2.576

Review 9.  Hepatitis C virus in Arab world: a state of concern.

Authors:  Mohamed A Daw; Aghnaya A Dau
Journal:  ScientificWorldJournal       Date:  2012-05-02

10.  Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors.

Authors:  Wiam A Alashek; Christopher W McIntyre; Maarten W Taal
Journal:  BMC Infect Dis       Date:  2012-10-20       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.